CurrentAetnaPolicy 0721

Intraoperative Radiation Therapy (IORT)

This clinical policy bulletin defines Aetna's coverage stance for intraoperative radiation therapy (IORT), including indications considered medically necessary, investigational indications, and related coding; it applies to Aetna members and providers rendering IORT services.

Policy Summary

PayerAetna

PolicyIntraoperative Radiation Therapy (IORT)

Policy CodePolicy 0721

Change TypeNo material change

Effective DateMar 17, 2006

Next Review DateAug 8, 2024

Key ActionObtain prior authorization documenting indication, planned IORT technique and dose, and whether supplemental external-beam radiotherapy is anticipated.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

4Medically necessary indications

4Breast selection criteria

13Experimental/Investigational examples

3Primary CPT codes

1,113 vs 1,119TARGIT-A randomized patients

~4%

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Approx. 5-yr absolute IBTR increase (IORT vs WBRT)

Coverage Criteria — When IORT Is Covered or Not

inv-01: Medically Necessary and Breast Selection Criteria

Aetna considers IORT medically necessary for the following when ALL criteria (for breast where specified) are met

Medically necessary indications: IORT is medically necessary for the treatment of cervical cancer, colorectal cancer, soft tissue sarcoma (including retroperitoneal sarcoma), and uterine cancer.

from policy medical necessity list

Breast - single-fraction electron-beam IORT at lumpectomy: Covered when ALL of the following are met: 1) Documented diagnosis of early stage (0, I or II) breast cancer; AND 2) Negative lymph nodes; AND 3) Technically clear surgical margins; AND 4) Used to treat tumors less than or equal to 5 cm in diameter.tumor size <= 5 cm

breast-specific selection criteria

inv-02: Experimental / Investigational (Not Medically Necessary)

Aetna considers IORT experimental and investigational for the following indications because effectiveness has not been established

Experimental/Investigational indications: Brain tumors (e.g., glioblastomas) and brain metastasis; Cholangiocarcinoma; Conjunctival neoplasms (e.g., lymphoma, sebaceous carcinoma, and squamous cell carcinoma); Gastric cancer; Head and neck cancers (e.g., esophageal cancer, and middle ear tumors); Osteosarcoma; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Spinal metastases; Sporadic renal angiomyolipoma; Thymoma; Vertebral metastases.

partial list from policy

inv-03: Early-stage breast cancer — selected use

Study-based contexts where IORT has been evaluated and may be considered:

IORT as alternative to whole-breast EBRT in selected early breast cancer: Randomized TARGIT-A trial enrolled women >=45 with invasive ductal carcinoma undergoing lumpectomy and found non-inferior 4-year local recurrence (1.20% IORT vs 0.95% EBRT) and similar major toxicity rates; up to ~15% in IORT arm required additional EBRT due to postop findings.TARGIT-A enrollment criteria and results

Applicable to selected patients; long-term data continue to mature.

ELIOT and IOERT evidence: Randomized ELIOT/IOERT trials reported higher 5-year local recurrence versus EBRT overall but identified low-risk subgroups with lower recurrence; single-fraction electron IOERT trials and series (e.g., 21 Gy cohorts) have reported acceptable toxicity and low short-term recurrence in selected patients.ELIOT/TARGIT comparative results

Selection and follow-up influence outcomes

Phase II and registry contexts:

inv-04: Non-breast cancer site evidence

Site-specific study findings and limitations:

Pancreatic cancer: Systematic reviews and retrospective analyses show inconsistent results; some meta-analyses suggest improved loco-regional control or survival in resectable disease but prospective randomized data are lacking and role remains controversial.evidence inconclusive

NCCN recommends IORT only at specialized centers

Gastric cancer: Matched retrospective series showed no survival benefit and increased surgical morbidity with IORT despite low loco-regional recurrence.no survival benefit

Increased perioperative complications observed

Biliary/hepatic tumors: IORT and advanced RT techniques permit dose escalation in biliary tumors but prognosis remains poor; integration of novel strategies is investigational.

inv-05: Study-based selection and outcomes

Clinical trial and study-based selection criteria and observed outcomes

TARGIT-A trial enrollment and risk-adapted approach: Women >=45 years with invasive ductal carcinoma randomized to TARGIT versus EBRT; risk-adapted strategy delivered supplemental EBRT for predefined adverse final-pathology features; supplemental EBRT was required in about 15.2% of TARGIT recipients.

Timing of IORT (pre- vs post-pathology) influenced recurrence rates

ELIOT trial findings: ELIOT (IOERT) reported higher 5-year ipsilateral recurrence overall (4.4% IOERT vs 0.4% EBRT) but identified a low-risk subgroup with 1.5% recurrence; authors emphasize strict institutional protocols for single-fraction IOERT selection.

Median follow-up reported ~5.8 years

Pre-excision IORT phase II findings: Phase II pre-excision IORT (Vanderwalde) enrolled patients >=48 years with invasive ductal carcinoma <=3 cm, node-negative; delivered 15 Gy IORT with immediate partial mastectomy and observed a 6-year ipsilateral event rate of 15%, with worse outcomes in cautionary/less favorable subgroups.

Suggests inadequate local control for less favorable early-stage cancers

inv-06: Site-specific evidence and conditional coverage considerations

Coverage considerations based on site-specific evidence and guideline statements

Brain metastases: IORT (permanent Cs-131 implants or intra-beam) has demonstrated feasibility and high local control in small prospective and non-randomized studies (e.g., Cs-131 trial: 24 patients, 100% local FFP; intra-beam prospective series: feasible with clinical benefit), suggesting IORT may be an option in selected patients with detailed procedural documentation and follow-up.

Data principally from small single-institution studies; larger trials needed

Pancreatic cancer: Systematic reviews and meta-analyses report inconsistent results; some pooled analyses suggest improved median survival ratio and reduced local recurrence with IORT in resectable pancreatic cancer, but NCCN views the role as controversial and recommends limiting IORT to specialized centers.

Prospective randomized phase III data are lacking

Breast cancer (early stage): Registry, single-institution, and meta-analytic data show increasing use of single-dose IORT/APBI with low short-term recurrence in carefully selected low-risk patients; randomized trials (TARGIT-A, ELIOT) indicate higher in-breast tumor recurrence compared with whole-breast RT and guidelines recommend caution or trial/registry use.

inv-07: Breast cancer — IORT coverage criteria

IORT in breast cancer may be considered only when ALL of the following selection criteria for 'suitable' patients are met or when used within research/registry contexts as specified:

Breast IORT suitability: Patient selection aligns with APBI 'suitable' criteria: age >=50 years; tumor size <=2 cm; non-lobular histology; pathologic node-negative or pNmic; Ki-67 <=20%; non–triple-negative receptor status; tumor grade 1–2.as stated

Derived from APBI consensus and Takanen cohort

Modality-specific constraints: Electron-beam IORT: restrict to women considered 'suitable' for partial breast irradiation (strong recommendation). Low-energy x-ray IORT (TARGIT/Intrabeam): recommend use only within a prospective registry or clinical trial per ASTRO CED and restricted to 'suitable' patients (weak recommendation).as stated

Modality and evidence-strength dependent

Counseling requirement:

inv-08: Evidence summary (no definitive coverage criteria)

Summary of evidence and guideline context found in this section

Thymoma - INTRABEAM IORT: Small non-randomized study reported safety of low-energy INTRABEAM IORT (~10 Gy) in stage II invasive thymoma without significant increase in operation- or radiation-related complications; long-term efficacy unconfirmed and NCCN does not list IORT for thymoma.

Evidence insufficient for definitive coverage decisions

Coding and coverage determinations for intraoperative radiation therapy (IORT) reference both the CPT procedure codes and the applicable ICD-10 diagnosis codes. CPT codes 77424, 77425, and 77469 are listed as covered when the policy’s medical necessity and selection criteria are met. CPT code 0735T is explicitly listed as not covered for the indications enumerated in this bulletin. Providers should document the clinical indications and selection-criteria elements (e.g., breast staging, node status, margins, tumor size) when submitting claims referencing the covered CPT codes. The policy also provides lists of ICD-10 codes that are covered when selection criteria are met (for example, ranges such as C50.011–C50.929 for breast and C49.4–C49.5 for retroperitoneal sarcoma) and ranges that are not covered for the investigational indications (for example, C25.0–C25.9 for pancreas, C16.0–C16.9 for stomach, and C37 for thymus).

Clinical guidance groups have characterized single‑fraction intraoperative radiation approaches for breast cancer as experimental pending longer-term results. The American College of Radiology’s Appropriateness Criteria noted that single‑fraction IORT had very limited follow-up at the time of their review and described it as an experimental approach with ongoing randomized trials and accrual necessary to establish long‑term local control and survival outcomes.

Clinical exclusion criteria reported in trial and pilot settings include patients with contraindications to radiation therapy, those with prior radiation to the same breast or chest, individuals with an extensive intraductal component, and tumors located in the axillary tail of the breast. These conditions were explicitly excluded from reported pilot studies and represent situations in which IORT would generally not be appropriate.

UpToDate advises that use of IORT for breast cancer should be limited to clinical trial settings because available randomized data suggest an association with a higher risk of in‑breast tumor recurrence compared with whole‑breast radiotherapy. Until longer‑term (10–15 year) outcomes are available, UpToDate recommends enrollment in trials rather than routine clinical use.

Caution is advised when considering IORT for patients with higher‑risk breast cancers. Randomized-trial and pooled analyses reported substantially greater absolute increases in ipsilateral breast tumor recurrence for grade 3, estrogen receptor–negative, or triple‑negative tumors (on the order of ~15–20% absolute increase in some analyses). The policy recommends avoiding IORT or using it only with particular caution in these higher‑risk subgroups.

The NCCN Thymomas and Thymic Carcinomas guideline (Version 1.2020) does not list intraoperative radiation therapy as a management or therapeutic option for thymoma. Small non‑randomized studies reporting safety (for example, low‑energy INTRABEAM at ~10 Gy) do not change the guideline absence of IORT in standard thymoma management.

This Clinical Policy Bulletin is provided as a general description of plan benefits for use in administering coverage and does not constitute a contract or guarantee of coverage. Participating providers remain responsible for verifying member benefits and obtaining any required authorizations per plan provisions.

Use of IORT for the indications listed in this bulletin as experimental and investigational is considered not medically necessary because effectiveness has not been established for those conditions (for example, brain tumors, pancreatic cancer, prostate cancer, spinal/vertebral metastases, cholangiocarcinoma, gastric cancer, and others enumerated in the policy).

In select series, increased perioperative morbidity has been observed without survival benefit — for example, a matched retrospective analysis in gastric cancer reported no improvement in 5‑year survival with IORT but a significantly higher overall surgical complication rate in the IORT group. Such findings support deeming IORT not medically necessary when it increases morbidity without improving survival.

Evidence is insufficient to establish the effectiveness of IORT for several indications. For pancreatic cancer, systematic reviews and nonrandomized studies have not demonstrated clear superiority of IORT versus other therapies in locally advanced or metastatic disease, and the policy states that novel strategies like IORT should preferably be investigated within clinical trials.

For early‑stage breast cancer outside of a clinical trial or registry, the policy cautions that randomized data (TARGIT‑A and ELIOT) suggest an increased risk of ipsilateral breast tumor recurrence with IORT compared with whole‑breast radiotherapy. Providers should counsel patients about this increased IBTR risk before selecting IORT outside of research settings.

The policy discourages routine use of IORT when the therapeutic goal is cancer control equivalent to whole‑breast radiotherapy unless the patient is enrolled in a clinical trial or registry. This recommendation is based on trial results showing higher local recurrence with IORT compared with WBRT and on guideline statements that support registry or trial‑based use for low‑energy x‑ray IORT.

Study‑level evidence for IORT in thymoma is limited to small, non‑randomized reports that describe safety (for example, low‑energy INTRABEAM at approximately 10 Gy) but do not confirm long‑term efficacy. The absence of IORT in NCCN thymoma guidance and the limited sample sizes in available studies may affect medical necessity determinations and support requests for additional justification.

Coding — CPT and ICD-10 Guidance

Covered CPT Codes (if selection criteria are met)CPTCovered

77424	Intraoperative radiation treatment delivery, x-ray, single treatment session
77425	Intraoperative radiation treatment delivery, electrons, single treatment session
77469	Intraoperative radiation treatment management

CPT Codes not covered for indications listed in the CPBCPTNot Covered

0735T

Preparation of tumor cavity, with placement of a radiation therapy applicator for intraoperative radiation therapy (IORT) concurrent with primary craniotomy (List separately in addition to code for primary procedure)

Other CPT codes related to the CPBCPT

19294	Preparation of tumor cavity, with placement of a radiation therapy applicator for intraoperative radiation therapy (IORT) concurrent with partial mastectomy (List separately in addition to code for primary procedure)
19301	Mastectomy, partial (eg, lumpectomy, tylectomy, quadrantectomy, segmentectomy)
19302	Mastectomy, partial; with axillary lymphadenectomy
77261-77299	Clinical treatment planning
77300-77399	Medical radiation physics, dosimetry, treatment devices, and special services
77401-77417	Radiation treatment delivery
77427-77499	Radiation treatment management
77750-77799	Clinical brachytherapy

ICD-10 Codes covered if selection criteria are metICD-10Covered

C18.0-C21.8	Malignant neoplasm of colon, rectosigmoid junction, rectum, anus and anal canal
C46.1	Kaposi's sarcoma of soft tissue
C49.4-C49.5	Malignant neoplasm of connective and soft tissue of abdomen and of pelvis [retroperitoneal sarcoma]
C50.011-C50.929	Malignant neoplasm of breast
C53.0-C54.9	Malignant neoplasm of cervix uteri and of corpus uteri
D05.00-D05.92	Carcinoma in situ of breast

ICD-10 Codes not covered for indications listed in the CPB (not all-inclusive)ICD-10Not Covered

C00.0-C15.9	Malignant neoplasm of lip, oral cavity, pharynx and esophagus [head and neck cancer]
C16.0-C16.9	Malignant neoplasm of stomach [gastric cancer]
C22.0-C22.8	Malignant neoplasm of liver and intrahepatic bile ducts [cholangiocarcinoma]
C25.0-C25.9	Malignant neoplasm of pancreas
C61	Malignant neoplasm of prostate
C64.1-C64.9	Malignant neoplasm of kidney, except renal pelvis
C69.00-C71.9	Malignant neoplasm of eye and adnexa, meninges and brain [head and neck cancer and brain tumors]

Citations and referenced guidance (no explicit billing codes in this excerpt)mixed

No codes listed

Breast tumor size threshold

Breast tumor size thresholdTumor size ≤ 5 cm

Provider Actions — Prior Authorization, Documentation, and Denial Risks

Prior Authorization

Prior Authorization Required

Prior authorization is required for covered IORT CPT codes and for IORT procedures where the member's benefit plan requires authorization. Requests should document that the patient meets the policy's medical necessity criteria and reference the specific covered CPT/ICD-10 codes. Providers must obtain prior authorization where required by the benefit plan; failure to do so may affect coverage.

Affected CPT codes include 77424 (IORT x-ray), 77425 (IORT electrons), and 77469 (IORT management) when selection criteria are met.
Include plan-specific authorization number and verify benefit plan prior-auth requirements before scheduling.

Prior Authorization

Prior Authorization — Clinical and Technical Details

Prior authorization requests for IORT should include the clinical indication, planned IORT technique and single-fraction dose, and whether supplemental external-beam radiation therapy (EBRT) is planned. For breast cancer, document whether a risk-adapted plan is intended (e.g., TARGIT approach with EBRT reserved for defined adverse pathology).

Essential items: diagnosis and stage, tumor size, nodal status, surgical margin status, histology, planned IORT device/energy (electrons vs low-energy x-ray vs brachytherapy), single-fraction dose and prescription depth/volume.

Definitions and Terminology

Intraoperative radiation therapy (IORT) — general definition

DefinitionTechnique to deliver a large single dose of high-energy radiation directly to the tumor site at the time of surgery using applicators/cones on linear accelerators, often with shielding of adjacent normal tissues; may also refer to intraoperative brachytherapy (temporary or permanent implantation of radioactive seeds).

TimingDelivered at the time of surgery as a single-fraction treatment to the exposed tumor bed.

PurposeAims to enhance local tumor control while protecting adjacent normal tissues through operative mobilization and shielding.

Targeted IORT (TARGIT)

DefinitionTechnique delivering a single intraoperative dose of low-energy x‑rays to the tumor bed during breast-conserving surgery (TARGIT/Intrabeam).

Trial context

Policy Summary

PayerAetna

PolicyIntraoperative Radiation Therapy (IORT)

Policy CodePolicy 0721

Change TypeNo material change

Effective DateMar 17, 2006

Next Review DateAug 8, 2024

Key ActionObtain prior authorization documenting indication, planned IORT technique and dose, and whether supplemental external-beam radiotherapy is anticipated.

SourceLink

On This Page

Prospective and registry series (including phase II cohorts and multi-institutional registries) have evaluated single-fraction IORT (common dose examples: 21 Gy single-fraction electrons; 14 Gy intra-beam for brain) reporting feasibility, cosmetic outcomes, and variable local control dependent on patient selection.

Used to inform selection but do not define coverage beyond policy criteria

investigational context

Preliminary/encouraging only

Retroperitoneal soft tissue sarcoma: IORT is used as a focal boost in some institutional series to improve local control, but no definitive randomized evidence establishes optimal timing, dosing, or survival benefit.institutional use

Balance toxicity to adjacent organs critically important

Head and neck recurrent cancer: HDR-IORT series report encouraging local control with acceptable morbidity in small cohorts; longer follow-up in larger cohorts is needed.small series

Often used after prior EBRT in recurrent disease

Prostate cancer: Phase I-II dose-finding and feasibility studies demonstrate IOERT is technically feasible with acceptable early toxicity, but long-term oncologic outcomes remain limited.early-phase evidence

Investigational outside trials

Bone sarcomas and vertebral/ spinal metastases: IORT approaches (including Kypho-IORT) provide focal dose intensification and mechanical stabilization in case series; evidence mainly from feasibility and observational studies.case series/feasibility

Further study required

Brain metastasis IORT/ Cs-131 implant series: Small series and phase I/II trials using permanent Cs-131 implants or intra-beam devices report high local freedom-from-progression (e.g., 100% local FFP in a 24-patient Cs-131 trial) and acceptable toxicity, supporting feasibility in select patients.

Follow-up durations are limited; multicenter trials warranted

Long-term outcomes remain necessary for definitive assessment

Soft tissue sarcoma / retroperitoneal STS: NCCN and institutional series note encouraging local control when IORT is used (often as a boost) in multidisciplinary protocols; ongoing trials are evaluating the optimal integration of IORT.

Consider use in specialized multidisciplinary centers or trials

Spinal metastases (Kypho-IORT): Kypho-IORT and related approaches have been reported as safe and feasible for palliative stabilization and local control in procedural series; evidence remains preliminary.

Often performed in centers with IORT-capable operating suites

Conjunctival neoplasms: Small flexible-film brachytherapy series (e.g., intraoperative 32P film) report preliminary recurrence-free outcomes in selected refractory conjunctival neoplasms; further study needed.

Case series evidence only

Clinician must counsel patient that randomized trials (TARGIT-A, ELIOT) demonstrated higher 5-year ipsilateral breast tumor recurrence with IORT compared with WBRT (approximate absolute increase ~4% over 5 years) and substantially higher absolute increases (15–20%) in high-risk biologic subtypes; patients should be informed and enrollment in trial/registry encouraged for low-energy x-ray IORT.

Patient counseling and documentation recommended prior to IORT

Planned EBRT fields, dose/fractionation (if any), and criteria that would trigger supplemental EBRT (pathology triggers).

Prior Authorization

Prior Authorization — Risk-Adapted Breast IORT

For breast-conserving surgery IORT performed within a risk-adapted strategy, prior authorization should capture the risk-adapted nature of the plan and note that supplemental EBRT was used in a subset of trial patients. Authorization should confirm eligibility consistent with the policy's selection criteria or trial-derived 'suitable' definitions.

Document whether the approach follows a trial-based risk-adapted protocol (e.g., TARGIT-A) and the anticipated percentage of patients expected to receive supplemental EBRT.
Note that supplemental EBRT was required in approximately 14–15% of patients in trials when adverse pathology was found.

Prior Authorization

Pancreatic IORT — Specialized-Center Prior Authorization

Pancreatic IORT is controversial and, per NCCN guidance, should be limited to specialized centers. Prior authorization for pancreatic IORT must indicate specialized-center capability and experience; deviations from specialized-center expectation may be denied.

Provide documentation of specialized-center designation, multidisciplinary tumor board review, surgeon/radiation oncologist IORT experience, and protocol under which IORT will be delivered.
Include literature justification or clinical trial enrollment if applicable; absence of specialized-center criteria may result in non-authorization.

Prior Authorization

Prior Authorization — Patient Selection

Patient selection and prior authorization notes: electron-beam IORT for partial-breast treatment should be restricted to women meeting 'suitable' APBI selection criteria. Low-energy x-ray IORT should be used within a clinical trial or registry per ASTRO CED statements; authorization should reflect these conditions.

For breast IORT, document age, tumor size, histology (non-lobular preferred), nodal status (pN0/pNmic), receptor status, grade, and Ki-67 when available.
When IORT is being requested outside of recommended selection criteria or outside a registry/trial, include rationale and supportive evidence; such cases carry higher denial risk.

Denial Risk

Denial Risk — Investigational Indications

Denial risk exists for investigational indications listed in the policy. IORT is considered experimental/investigational for multiple disease sites; requests for these indications should be expected to be denied unless compelling evidence or trial context is provided.

Common investigational indications include brain tumors (primary glioblastoma), cholangiocarcinoma, gastric cancer, pancreatic cancer (outside specialized centers), prostate cancer, spinal metastases, thymoma, and others listed in the policy.
Provide clinical trial enrollment information or prospective registry documentation if proposing IORT for investigational indications.

Denial Risk

Denial Risk — Complication and Outcome Concerns

Complication- and outcome-related denial risk: evidence of increased surgical morbidity or lack of survival benefit in some indications may justify denial or the need for additional documentation. Prior authorization should address perioperative risk and expected benefit.

Examples: higher surgical complications reported with IORT in some gastric cancer series; provide justification if used for such indications.
Include anticipated perioperative morbidity mitigation plans and multidisciplinary assessment.

Denial Risk

Denial Risk — Clinical Exclusions and Contraindications

Clinical exclusion-related denial risks should be documented and considered before authorization. Contraindications or exclusion criteria in the policy (e.g., prior radiation to the same breast/chest, contraindications to radiation, extensive intraductal component, tumor in axillary tail) may disqualify a patient from coverage.

Document prior radiation history to the same site, presence of extensive intraductal component, tumor location (axillary tail), and any absolute contraindications to radiation.
If any exclusion applies, prior authorization should be denied or require clear rationale for exception.

Note

Counseling and Registry Expectations

Providers should counsel patients on expected comparative risks and consider enrollment in registries for certain IORT modalities. For breast cancer, counsel that trials showed higher ipsilateral breast tumor recurrence (IBTR) with some IORT approaches versus whole-breast irradiation, and document that counseling in the authorization record.

Document shared decision-making that includes discussion of increased IBTR risk and alternative options such as hypofractionated whole-breast RT.
When low-energy x-ray IORT is used, document registry enrollment or trial participation per ASTRO CED guidance.

Documentation Required

Documentation to Support Coverage

Documentation to support coverage must include clinical and procedural records consistent with covered CPT and ICD-10 codes and the medical necessity criteria in the policy. Prior authorization records should be retained and made available upon request.

Include operative note, pathology report, final margin status, staging, imaging, and radiation oncology treatment plan.
Include the CPT/ICD-10 codes being billed and cross-reference to the policy's covered code list.

Documentation Required

Essential Clinical Documentation

Essential clinical documentation required for authorization: tumor stage, nodal status, margins, single-fraction dose, device/energy used, prior radiation history, and any planned or prior EBRT. Include criteria that would trigger supplemental EBRT and multidisciplinary review notes.

Tumor size and stage (T/N), histology, margin distance, and presence/absence of extensive intraductal component.
Planned IORT dose (e.g., 21 Gy electrons, 20 Gy low-energy x-ray, or Cs-131 brachytherapy prescription) and prescription depth/volume.

Documentation Required

Required Clinical and Procedural Documentation

Required clinical documentation at the time of procedure and for post-procedure review: informed consent specific to IORT, operative details, resection margin measurement (example: 1 cm when applicable), intraoperative decisions, frozen-section pathology when used, and delivered dose/seed counts for brachytherapy.

Informed consent describing risks/benefits and alternatives including WBI or hypofractionated EBRT.
For brachytherapy (brain implants), include cavity size/volume, number of seeds, seed activity, and dosimetry summary.

Documentation Required

Intraoperative Decision and Targeting Documentation

Intraoperative decision-making and targeting documentation should capture the rationale for delivering IORT, any change in plan based on frozen-section pathology or intraoperative findings, and exact targeting/positioning information.

Record intraoperative findings that altered the plan (e.g., positive margin, unexpected nodal disease) and resulting actions (e.g., decision to abort IORT or to plan supplemental EBRT).
Include shielding or mobilization techniques used to protect organs at risk.

Documentation Required

IORT Procedural and Dosimetric Documentation (Brain/Brachytherapy)

IORT procedural and dosimetric documentation for brain implants (e.g., Cs-131) must include histology, cavity dimensions/volume, number of seeds used, activity per seed and total activity, and delivered dose with prescription depth. These technical details are required for authorization and post-procedure review.

Provide seed model, number, activity (mCi) per seed, total activity, cavity volume (cm3), and prescription dose (e.g., 80 Gy at 5 mm).
Include immediate postoperative imaging if used to confirm implant positioning.

Note

Policy Documentation and Provider Responsibility

Policy documentation and administrative responsibilities: include the policy history and review dates in authorization records when applicable. Clinical Policy Bulletins are intended to assist in administering plan benefits; participating providers remain responsible for medical advice and treatment decisions.

Reference policy number 0721 and effective date 2006-03-17 in authorization documentation when relevant.
Providers remain responsible for patient care; CPBs do not guarantee coverage and are not medical advice.

Step Therapy

Step Therapy / Sequencing Considerations

Step therapy and sequencing notes: there is no mandated step therapy for IORT in this policy. Consider whole-breast hypofractionated EBRT as an established alternative when treatment duration or long-term data for IORT are concerns. IORT is often part of multidisciplinary care and can be used as a boost in selected cases.

When requestors cite convenience as primary rationale, document consideration of hypofractionated WBRT schedules as a viable alternative.
No formal step-through therapies are required by this policy; document the clinical reasoning for selecting IORT over alternatives.

Denial Risk

Potential Denial Rationale and Evidence Expectations

Potential denial rationale: limited evidence for certain devices/indications (for example, INTRABEAM for invasive thymoma or pancreatic uses outside specialized centers) may justify denial or requirement for additional documentation or registry/trial enrollment.

Requests for uncommon indications should include high-quality evidence or clinical trial/registry participation to avoid denial.
Administrative denials may follow when documentation does not meet policy criteria or when benefit plan provisions are not followed.

Evaluated in the randomized TARGIT-A trial comparing targeted IORT versus whole-breast EBRT with a risk-adapted approach where supplemental EBRT was given for adverse final pathology findings.

Risk-adapted useIn TARGIT-A, up to ~15% of patients who received TARGIT required supplemental EBRT based on post-operative pathology.

HDR-IORT (high-dose-rate intraoperative brachytherapy)

DefinitionHigh-dose-rate intraoperative brachytherapy delivered with a brachytherapy applicator (example: Harrison-Anderson-Mick applicator with Iridium-192) delivering a single intraoperative fraction.

Dose exampleReported median single-fraction dose was 15 Gy (range 10–20 Gy) in a recurrent head-and-neck series using HDR-IORT.

TARGIT / TARGIT-A — trial identifier and summary

Trial identifierTARGIT-A (Targeted Intraoperative Radiotherapy-A) randomized trial

PopulationWomen aged ≥45 years with invasive ductal carcinoma undergoing breast-conserving surgery, randomized to TARGIT versus whole-breast EBRT.

Key findingsRisk-adapted approach with supplemental EBRT given for adverse pathology; 4-year local recurrence estimates were similar (1.20% IORT vs 0.95% EBRT in earlier report), with later analyses showing higher 5-year IBTR in IORT in some analyses.

ELIOT — electron IORT trial

DefinitionELIOT — randomized trial of intraoperative electron radiotherapy (IOERT) comparing single-dose electron IORT versus whole-breast EBRT in early breast cancer.

Key resultReported 5-year recurrence rates of 4.4% for IOERT versus 0.4% for EBRT with a low-risk subgroup identified (5-year recurrence 1.5%).

Permanent Cs-131 brachytherapy implant

DefinitionPermanent Cs-131 brachytherapy implant involves placement of stranded cesium-131 seeds as permanent volume implants at the resection cavity to deliver a prescribed dose.

Dosing examplePrescription dose reported as 80 Gy at a 5-mm depth from the resection cavity surface in a phase I/II brain metastasis trial.

Cs-131 permanent brachytherapy implant — technical/dosing details

Stranded seedsStranded (131)Cs seeds placed as permanent volume implants at time of resection.

Trial dosing exampleExample dosing in the trial was 80 Gy prescribed at 5 mm from the cavity surface; median number of seeds 12 (range 4–35) and median activity ~3.82 mCi per seed.

Intra-beam IORT (portable low‑energy x‑ray device)

DefinitionIntra-beam IORT uses a portable intraoperative device delivering a single fraction of low-energy x‑rays to the resection cavity during surgery (example: 14 Gy to a 2‑mm depth).

Feasibility dataNon-randomized prospective study treated 23 patients with solitary brain metastases delivering 14 Gy to 2‑mm depth showing feasibility and acceptable outcomes.

Intraoperative radiation therapy (IORT) — alternate/concise definition

Alternate definitionIORT: delivery of radiation at the time of surgery, typically as a single‑fraction dose to the exposed tumor bed with operative mobilization/shielding of normal tissues; may include intraoperative brachytherapy techniques.

Decision pointThe decision to deliver IORT is often made intraoperatively based on clinical and frozen‑section pathology evaluation.

Selection criteria for suitability for partial breast irradiation (APBI)

AgeGenerally age ≥ 50 years for APBI 'suitable' selection.

Tumor sizeTumor ≤ 2 cm for APBI 'suitable' selection (policy notes APBI criteria for suitability).

Histology / node statusNon‑lobular histology; node‑negative or micrometastasis (pN0/pNmic).

Biomarkers / gradeKi‑67 ≤ 20% and non–triple‑negative receptor status; grade 1–2 tumors preferred.

Breast cancer staging — categories and relevance

Staging categoriesStages 0 through IV (Stage 0 = DCIS; Stage I = small invasive tumor; Stage II = tumor up to 5 cm or node involvement; Stage III = advanced local/regional disease; Stage IV = metastatic).

Tumor size relevanceStage II may include tumor between 2 and 5 cm; policy uses staging to define 'early stage (0, I, II)' for breast IORT eligibility.

Definitions / Review History — references and metadata

Definitions and linksPolicy provides links to Definitions and Review History for additional policy‑specific terms and revision details.

Policy review datesLast review 09/22/2023; Next review 08/08/2024; Effective date 03/17/2006.

Where to find detailsSee policy 'Definitions' and 'Review History' links in the document footer for full lists and revision notes.